Charles Zhuang 庄怀超 SFC CE: BTE209 微信: zhuangcharles; 电话: (852) 9748 7114; 02 Dec 2025 环球富盛理财有限公司 中国罕王 China Hanking Holdings (3788.HK) ➢ 邱博士及 Cygnet Gold 少数股东对罕王黄金增资。基于对 Cygnet 金矿项目及罕王黄金未来发展的信心，邱博士及 Cygnet Gold 少数股东拟认购罕王黄金的新发行股份。 2025 年 10 月 27 日，公司附属公司罕王黄金与 Qiu Family 及 Golden Resource（均由邱博士控制）订立认购协议，据此，罕王黄金同意配发及发行，而 Qiu Family 及 Golden Resource 同意以每股 2.62 港元的认购价认购 8,700,000 股罕王黄金股 份（邱博士认购增资），此认购价与公司于 2025 年 9 月 30 日所公布与六名认购人订立的认购协议所载认购价相同。 同日，罕王黄金与 Cygnet Gold 的少数股东 订立认购协议，据此，罕王黄金同意配发及发行，而 Cygnet Gold 的少数 ...

Investment Rating - The investment rating for Tencent Holdings is "Buy" [7] Core Insights - The company's gaming business is expected to grow robustly driven by a new product cycle, while the video account advertising business remains highly prosperous, likely becoming a major source of revenue growth [1][2] - In Q3 2025, Tencent's online gaming revenue (excluding social) reached 636 billion yuan, a year-on-year increase of 23%. Domestic market revenue was 428 billion yuan, up 15%, exceeding Bloomberg's consensus estimate of 423 billion yuan, primarily due to the contribution from "Delta Operation" and continued revenue growth from existing games [1] - International market revenue was 208 billion yuan, a 43% year-on-year increase, surpassing Bloomberg's consensus estimate of 181 billion yuan, driven by record highs in daily active users and revenue for "Clash Royale" and growth from "PUBG: MOBILE" [1] - The introduction of a 15% commission agreement between Apple and Tencent regarding WeChat mini-game payments is expected to open up payment opportunities in the long term, despite short-term challenges in commission avoidance methods [3] - The company's marketing services revenue in Q3 2025 was 362 billion yuan, a 20.8% year-on-year increase, driven by improvements in eCPM and expansion of advertising inventory [4] Financial Forecasts - Projected revenues for Tencent from 2025 to 2027 are 748.76 billion yuan, 835.25 billion yuan, and 921.90 billion yuan, with year-on-year growth rates of 13%, 12%, and 10% respectively [5] - Adjusted net profits for the same period are forecasted to be 266.16 billion yuan, 293.21 billion yuan, and 321.51 billion yuan, with growth rates of 20%, 10%, and 10% respectively [5] - The valuation method applied suggests a target price of 794.73 HKD per share for 2026, indicating a potential upside of 30% [5]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$41.40, representing a potential upside of 27% from the current price of HK$32.58 [1][7][10]. Core Insights - The company is expected to achieve profitability in Q4 2025, with significant sales growth anticipated in the following year. The revenue for Q3 2025 was reported at RMB 407 million, with a decline of 10.6% quarter-on-quarter [5][8]. - The EM platform has gained market recognition, and the potential for Robotaxi is substantial, with expectations of increased demand for lidar units [6][10]. - The report projects a significant increase in radar sales, with estimates of 2.3 million units in 2026 and 3.1 million units in 2027, driven by the growth in the robotics sector [7][9]. Financial Summary - Revenue projections for the company are as follows: RMB 2,204 million in 2025, RMB 3,126 million in 2026, and RMB 4,038 million in 2027, reflecting a year-on-year growth of 33.6% in 2025 and 41.8% in 2026 [8][9]. - The adjusted net profit is expected to improve significantly, with estimates of RMB -83 million in 2025, RMB 230 million in 2026, and RMB 533 million in 2027 [9][10]. - The company anticipates a gross margin of 27.3% in 2025, increasing to 30.2% in 2026 and 31.2% in 2027 [9][10].

网龙（00777.HK） AI 赋能游戏教育，多元投资增厚业绩 2025 年 12 月 02 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 7,101 | 6,047 | 4,641 | 4,932 | 5,267 | | 同比(%) | (9.73) | (14.84) | (23.25) | 6.27 | 6.79 | | 归母净利润（百万元） | 550.00 | 311.00 | 401.28 | 674.49 | 682.41 | | 同比(%) | (34.05) | (43.45) | 29.03 | 68.09 | 1.17 | | EPS-最新摊薄（元/股） | 1.04 | 0.59 | 0.76 | 1.27 | 1.28 | | P/E（现价&最新摊薄） | 9.89 | 17.50 | 13.56 | 8.07 | 7.97 | 证券研究报告·海外公司深度·软件服务(HS) [Ta ...

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of HKD 5.69, reflecting a 5.0% increase from the previous target price [2][7]. Core Insights - The company achieved a revenue of RMB 16.70 billion for FY9/25, representing a year-on-year growth of 17.0%. The gross profit margin improved to 25.1%, and the adjusted net profit increased by 38.7% to RMB 1.36 billion [3][14]. - The self-operated pharmaceutical business generated revenue of RMB 14.38 billion, growing by 18.6% year-on-year, driven by increases in pharmaceutical and medical device categories. The number of self-operated SKUs expanded significantly [18][14]. - The pharmaceutical e-commerce platform business reported revenue of RMB 1.84 billion, up 7.5% year-on-year, with improvements in operational capabilities and a significant increase in the number of merchants [18][14]. - The healthcare and digital services business generated revenue of RMB 480 million, reflecting an 8.2% year-on-year growth, with a notable increase in contracted healthcare professionals [18][14]. - The company has optimized its supply chain efficiency, with a reduction in fulfillment costs and an overall operating expense ratio of 18.3%, down 0.9 percentage points [15][14]. Financial Forecasts - Revenue forecasts for FY26 and FY27 are set at RMB 34.90 billion and RMB 39.38 billion, respectively, indicating year-on-year growth of 14.1% and 12.8% [16][7]. - Adjusted net profit forecasts for FY26 and FY27 are RMB 2.48 billion and RMB 2.83 billion, representing growth rates of 27.1% and 14.3% [16][7]. - The company's equity value is projected to be HKD 92.08 billion, corresponding to a share price of HKD 5.69 per share based on a DCF valuation [16][7].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company focuses on the development of optical imaging, fingerprint recognition modules, and automotive electronic components, aiming to enhance its product matrix and transition from a consumer electronics imaging solution provider to a core component supplier for smart hardware [6][15]. - The company is expected to benefit from optical innovation and the wave of automotive intelligence, leading to steady improvements in profitability and market share [15]. Summary by Sections Company Overview - The company is committed to the synergistic development of imaging and fingerprint recognition, focusing on high-end manufacturing upgrades [6][15]. - It aims to grow into a technology enterprise providing integrated machine vision and human vision solutions [15]. Mobile Camera Module Business - The company holds a leading global market share in mobile camera modules, with a focus on enhancing the structure of its products [7][27]. - The market for mobile camera modules is expected to continue its stable growth, driven by increasing smartphone penetration and consumption upgrades [30][32]. - The sales proportion of high-end mobile camera modules (32M pixels and above) reached 53.4% in the first half of 2025 [7][27]. Other Camera Module Business - The IoT and automotive camera markets are expanding rapidly, with the company seeing a 47.9% year-on-year growth in sales for these modules [8][36]. - The global automotive camera module market is projected to reach USD 27.3 billion by 2025, with the company aiming to replicate its mobile camera market position in this sector [8][36]. Fingerprint Recognition Module Business - The market for ultrasonic fingerprint recognition modules is gradually expanding, with significant improvements in sales and product structure leading to increased gross margins [9][46]. - The company reported that its sales of ultrasonic fingerprint recognition modules in the first half of 2025 exceeded the total sales for 2024 [9][48]. Financial Forecast and Investment Recommendation - Revenue projections for the company are estimated at RMB 20.447 billion, RMB 22.854 billion, and RMB 26.331 billion for 2025, 2026, and 2027, respectively, with corresponding net profits of RMB 714 million, RMB 909 million, and RMB 1.138 billion [10][12]. - The company's P/E ratios for the same years are expected to be 14.5x, 11.3x, and 9.1x, which are lower than the industry averages [10][12].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% from the current price [5][10]. Core Insights - The company plans to repurchase up to approximately 104 million shares, which is about 9.7% of its total shares, signaling management's confidence in the company's future and belief that the stock is undervalued [6][7]. - The company has received its first Class III medical device certification for its recombinant type I α1 collagen product, marking its entry into the injectable aesthetic medicine market, which is expected to drive future growth [7]. - Despite recent stock price adjustments due to market conditions and lower-than-expected sales during the Double Eleven shopping festival, the report suggests that the stock has sufficiently adjusted and is poised for recovery [7]. Financial Projections - The company is projected to achieve net profits of RMB 2.43 billion, RMB 2.98 billion, and RMB 3.64 billion for the years 2025, 2026, and 2027, respectively, reflecting year-over-year growth rates of 17.8%, 22.5%, and 22.2% [9]. - Earnings per share (EPS) are expected to be RMB 2.27, RMB 2.78, and RMB 3.40 for the same years, with corresponding year-over-year growth rates of 8.1%, 22.5%, and 22.2% [9]. - The price-to-earnings (P/E) ratios are projected to decrease from 15x in 2025 to 10x in 2027, indicating a potential increase in value as the company grows [9]. Shareholder Information - The major shareholder is Fan Daidi, holding 55.13% of the shares, which indicates a strong control over the company [1]. - The company's market capitalization is approximately HKD 41.08 billion, with a current share price of HKD 36.58 [1]. Market Performance - The stock has experienced a significant decline, with a 24.4% drop over the past month and a 32.07% drop over the past three months [1]. - The stock price has fluctuated between a high of HKD 82.99 and a low of HKD 35.72 over the past year [1]. Product Portfolio - The company's product mix is heavily weighted towards functional skincare products, which account for 78.6% of total sales, while medical dressings contribute 23.3% and health products account for 0.3% [2].

Investment Rating - The report maintains a "Buy" rating for China Water Affairs (855 HK) with a target price adjusted to HKD 6.52, reflecting a potential upside of 10.1% from the current price of HKD 5.92 [5][8]. Core Insights - Despite a decline in overall revenue and net profit for FY26H1, the core water supply business showed resilience with a revenue increase of 4.5% and a sales volume increase of 5.0% [2][5]. - The company has accelerated its water price adjustments, with 8 projects approved for price increases, surpassing the annual target of 8 to 10 projects [3][5]. - A significant reduction in capital expenditure by 31.8% to HKD 12.4 billion in FY26H1 is expected to support the company's high dividend policy [4][5]. Financial Performance Summary - For FY26H1, total revenue and net profit decreased by 12.9% and 24.4% year-on-year, amounting to HKD 5.18 billion and HKD 570 million respectively [1][5]. - The water supply connection revenue fell by 28.6% to HKD 560 million, primarily due to fluctuations in the mainland real estate market [1][5]. - The wastewater treatment service revenue increased by 14.5% to HKD 360 million, driven by the Huizhou Mobil project contributing revenue since FY25 [2][5]. Revenue and Profit Forecast Adjustments - The forecast for shareholder net profit has been reduced by 10.8%, 14.8%, and 14.8% for FY26, FY27, and FY28 respectively [5][17]. - The target price adjustment reflects these changes, with the new estimates indicating a decrease in revenue projections for FY26 to HKD 9.899 billion, down from previous forecasts [5][17].

Investment Rating - The report does not explicitly state an investment rating for the company, but it suggests that the current macro environment continues to exert operational pressure on the company, indicating a cautious outlook on its performance [4]. Core Insights - The company reported a revenue decline of 5.4% year-on-year to HKD 4.036 billion for FY26H1, with adjusted EBITDA down 29.4% to HKD 243 million, and a net profit attributable to shareholders down 67.6% to HKD 46.7 million. The decline is attributed to weak restaurant performance in both Hong Kong and mainland China, as well as a normalization of consumer spending patterns [1][2]. - In response to the changing operational environment, the company is implementing significant business restructuring focused on six key areas: cost optimization, consolidation of advantageous business segments, restructuring of the fast-food segment, transformation of store models, integration of production lines, and exploring new business opportunities [3]. Summary by Relevant Sections Financial Performance - Revenue decreased by 5.4% year-on-year to HKD 4.036 billion, with specific declines in various segments: fast food (-5.9%), casual dining (-5.6%), institutional dining (-4.3%), and others (-8.1%). Mainland revenue fell by 3.8%. Net profit attributable to shareholders dropped by 67.6%, and when excluding fair value losses from investment properties, the decline was 59.4% [1][2]. Business Restructuring - The company is focusing on six main areas for restructuring: 1. **Cost Optimization**: Aiming for a 20% reduction in rental costs over the next three years and consolidating procurement for key ingredients to lower costs [3]. 2. **Strengthening Core Businesses**: Despite revenue impacts from closing inefficient stores, profitability in institutional and casual dining is improving [3]. 3. **Fast Food Segment Overhaul**: Addressing significant operational pressures by optimizing 220 fast-food outlets, particularly underperforming large and small stores [3]. 4. **Store Model Transformation**: Shifting focus from large stores to smaller models, with target sizes as low as 1,500 square feet to enhance operational flexibility [3]. 5. **Production Line Integration**: Strategically relocating production functions to mainland China to mitigate ongoing operational cost pressures in Hong Kong [3]. 6. **New Business Opportunities**: Actively seeking potential acquisition opportunities [3]. Investment Considerations - The ongoing macroeconomic changes are expected to continue impacting the company's operations, and while the restructuring efforts aim to restore confidence, a full recovery in performance is anticipated to take time. However, the high dividend yield (approximately 7% based on FY25 dividends) may provide some support for the stock price [4].

Charles Zhuang 庄怀超 SFC CE: BTE209 微信: zhuangcharles; 电话: (852) 9748 7114; 02 Dec 2025 环球富盛理财有限公司 紫金黄金国际 Zijin Gold International Company (2259.HK) 全球资源并购成绩优异，成本管控能力强大 Excellent performance in global resource mergers and acquisitions & Strong cost control capabilities 最新动态 ➢ 哈萨克斯坦斯坦 Raygorodok 金矿项目收购完成交割。紫金矿业控股子公司紫金黄金国际通过全资子公司收购哈萨克 斯坦斯坦 Raygorodok 金矿（RG 金矿）100%权益。鉴于协议中约定的交割先决条件已全部实现或豁免，本次收购已 于 2025 年 10 月 10 日完成交割，紫金黄金国际现已持有 RG 金矿 100%权益。根据紫金黄金国际招股说明书显示， 截至 2025 年 6 月 30 日，RG 金矿项目保有资源量：控制+推断级别矿石量 2.08 亿吨，金平均 ...